Pfizer spent $7 billion in 2025 to acquire Metsera, adding late-stage weight-loss therapies to its portfolio. Pfizer's last ...

In quick succession, first Oppenheimer analyst Brian Schwartz estimated Oracle stock is worth $275 a share, then Mizuho ...

GLP-1 weight-loss drugs burst onto the scene when Novo Nordisk (NVO-2.76%) introduced Wegovy to the world. There was so much ...

On the heels of this news, Northland Securities analyst Gus Richard upgraded Intel to outperform (buy), from market perform ...

A stock that just hit a 52-week low doesn't usually need much to bounce. NuScale Power ( SMR +15.00%) found that out in ...

Last month's fiscal second quarter was a perfect example of Nvidia stock perpetually scaling the wall of worry. Bears were ...

Meanwhile, Lockheed Martin stock costs barely 19.2 times earning -- and less than 14 times free cash flow. Weighed against ...

Alphabet's stock has some goofy things going on with its valuation metrics.

The value of the government's stake is unclear, as the release just said that the Dept. of Commerce will receive a minority, ...

If Casgevy continues to gain adoption while CTX310 progresses into late-stage development and Zugo-cel demonstrates ...

Impressively, Starbucks has produced four straight quarterly same-store (comps) increases. That includes its fiscal ...

AMD has clear exposure to the AI build-out via its data center division, which supplies GPUs and other computing components ...